ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Kineta Inc

Kineta Inc (KA)

0.4613
-0.0067
(-1.43%)
Closed May 25 4:00PM
0.4745
0.0132
(2.86%)
After Hours: 6:47PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.4745
Bid
0.44
Ask
0.475
Volume
21,471
0.442001 Day's Range 0.4895
0.3339 52 Week Range 5.39
Market Cap
Previous Close
0.468
Open
0.47
Last Trade Time
Financial Volume
$ 9,973
VWAP
0.464506
Average Volume (3m)
408,496
Shares Outstanding
10,393,567
Dividend Yield
-
PE Ratio
-1.39
Earnings Per Share (EPS)
-1.36
Revenue
5.44M
Net Profit
-14.1M

About Kineta Inc

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy. Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Kineta Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KA. The last closing price for Kineta was $0.47. Over the last year, Kineta shares have traded in a share price range of $ 0.3339 to $ 5.39.

Kineta currently has 10,393,567 shares outstanding. The market capitalization of Kineta is $19.64 million. Kineta has a price to earnings ratio (PE ratio) of -1.39.

KA Latest News

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no...

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any...

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...

Kineta Announces Restructuring and Exploration of Strategic Alternatives

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0051-1.063386155130.47960.50.44651110.47052248CS
4-0.1514-24.18916759870.62590.650.39896400.54799423CS
12-0.4637-49.42442975910.93821.33070.33394084960.57309455CS
26-2.8055-85.53353658543.284.770.33392069960.70375384CS
52-2.5355-84.23588039873.015.390.33391155980.94419908CS
156-8.4055-94.65653153158.8890.3339907071.35875159CS
260-8.4055-94.65653153158.8890.3339907071.35875159CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

KA Discussion

View Posts
INV4 INV4 1 month ago
Thanks Gail!

HOD 0.74 so far today 😃

$KA
๐Ÿ‘๏ธ0
gail gail 1 month ago
its up 17% so โ€ฆโ€ฆ

โ€ฆ.

far today it shows, so im happy for you.
👍️ 1
INV4 INV4 1 month ago
Ok lol 😄 Well I like the Float (6.59M) / OS (10.96M).

(I've seen such an $8 price target with $OCEA when it was trading at $0.50 cents or something and it hit $7.79. I took a small starter here... Whatever happens, it's all good).

KINETA INC (KA):
Shares Outstanding 10.96M
Shares Change (YoY) +124.40%
Shares Change (QoQ) +8.20%
Owned by Insiders (%) 29.25%
Owned by Institutions (%) 12.05%
Float 6.59M

GLTY

$KA
๐Ÿ‘๏ธ0
gail gail 1 month ago
moved on to bigger and better things, lol
๐Ÿ‘๏ธ0
INV4 INV4 1 month ago
Have you seen this price target? I don't know if that target is realistic/achievable here?

================

Kineta (KA) Price Target Increased by 25.58% to 13.77
April 17, 2024 โ€” 08:19 pm EDT

The average one-year price target for Kineta (NasdaqCM:KA) has been revised to 13.77 / share. This is an increase of 25.58% from the prior estimate of 10.96 dated March 28, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 13.64 to a high of 14.18 / share. The average price target represents an increase of 2,770.54% from the latest reported closing price of 0.48 / share.

https://www.nasdaq.com/articles/kineta-ka-price-target-increased-by-25.58-to-13.77

$KA
๐Ÿ‘๏ธ0
gail gail 1 month ago
in a good way? i see we are moving up now.
๐Ÿ‘๏ธ0
Awl416 Awl416 1 month ago
Watch out
๐Ÿ‘๏ธ0
Awl416 Awl416 2 months ago
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
KA new 52 week lo
๐Ÿ‘๏ธ0
AJ Freely AJ Freely 10 months ago
$KA - Up 7% Pre-Market/ Current Price $2.48
To Receive $5 Million Milestone Payment from Merck & eligible to receive additional milestone payments totaling up to $255m associated with the successful development of marketed products for pipeline program | 6/20.23
๐Ÿ‘๏ธ0
makinezmoney makinezmoney 1 year ago
$KA : Here you go............


https://investorshub.advfn.com/Starry-GROUP-Holdings-41712

Merr Christmas



GO $KA
๐Ÿ‘๏ธ0
tw0122 tw0122 1 year ago
Can you get them to open up comments on STRY you have clout.. Lol up over 1,436 percent biggest runner today..

Starry got delisted
๐Ÿ‘๏ธ0
makinezmoney makinezmoney 1 year ago
$KA: ReverseMerger with Yumanity Thera completed


https://kinetabio.com/

Added 10k here at $4.50 !!!!!!!!!!


LETS GOOooooooooooooooooooooooooooooooooo


The Company
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patientsโ€™ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kinetaโ€™s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies.
Kineta has established its immuno-oncology focused platform aimed at developing fully human antibodies to address the major mechanisms of cancer immune resistance. With drug candidates expected to enter the clinic and additional immuno-oncology assets in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.

Kineta has assembled an experienced management team, a seasoned research and development team, an immuno-oncology focused scientific advisory board, an enabling technology platform and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.


GO $KA
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock